JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Scope & Guideline

Advancing Medicinal Chemistry for Tomorrow

Introduction

Explore the comprehensive scope of JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1475-6366
PublisherTAYLOR & FRANCIS LTD
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 1985 to 1996, from 1998 to 1999, from 2002 to 2024
AbbreviationJ ENZYM INHIB MED CH / J. Enzym. Inhib. Med. Chem.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The Journal of Enzyme Inhibition and Medicinal Chemistry primarily focuses on the discovery and development of enzyme inhibitors and their medicinal applications. The journal emphasizes the integration of synthetic chemistry, biological evaluation, and computational methods to advance drug discovery and therapeutic strategies.
  1. Enzyme Inhibition Research:
    The journal publishes articles that explore the mechanisms, efficacy, and selectivity of various enzyme inhibitors, focusing on their potential therapeutic applications in diseases such as cancer, diabetes, and infectious diseases.
  2. Medicinal Chemistry:
    Papers often highlight the design, synthesis, and biological evaluation of novel compounds that act as enzyme inhibitors, showcasing the intersection of chemistry and biological efficacy.
  3. Computational Drug Design and Molecular Modelling:
    The journal features studies that utilize computational methods, such as molecular docking and dynamics simulations, to predict the efficacy and selectivity of enzyme inhibitors, aiding in the rational design of new drugs.
  4. Natural Products and Derivatives:
    Research on natural compounds and their derivatives as enzyme inhibitors is prominently featured, emphasizing the exploration of traditional medicine and natural sources for novel therapeutic agents.
  5. Targeted and Multi-targeted Therapeutics:
    The journal explores the development of multi-targeted inhibitors that can simultaneously modulate multiple pathways, reflecting a growing trend in personalized medicine and complex disease treatment.
The Journal of Enzyme Inhibition and Medicinal Chemistry has identified several emerging trends reflecting the evolving landscape of enzyme inhibition research and medicinal chemistry.
  1. COVID-19 Therapeutics:
    There has been a significant increase in research focused on developing inhibitors targeting SARS-CoV-2, particularly through enzyme inhibition strategies, reflecting the urgency and relevance of this global health crisis.
  2. Dual and Multi-target Inhibitors:
    The trend towards discovering compounds that can inhibit multiple targets simultaneously is gaining momentum, as researchers seek to create more effective treatments that can address complex disease mechanisms.
  3. Artificial Intelligence and Machine Learning in Drug Discovery:
    Increasingly, studies are incorporating AI and machine learning techniques to enhance drug discovery processes, particularly in predicting the interactions and efficacy of enzyme inhibitors.
  4. Personalized Medicine Approaches:
    Research is increasingly focusing on tailoring therapies to individual patients' profiles, particularly in cancer treatment, which has led to a rise in studies on personalized enzyme inhibitors.
  5. Sustainable and Green Chemistry Practices:
    There is a growing emphasis on sustainable practices in the synthesis of enzyme inhibitors, including the use of environmentally friendly solvents and methodologies, reflecting wider trends in the scientific community towards sustainability.

Declining or Waning

While the journal continues to focus on a range of topics within enzyme inhibition and medicinal chemistry, certain themes have seen a decline in prominence or frequency in recent publications.
  1. Traditional Medicinal Approaches:
    Research focusing solely on traditional medicinal compounds without extensive modification or synthetic approaches appears to be declining, as more emphasis is placed on novel synthetic pathways and targeted therapies.
  2. Single-target Inhibitors:
    The trend towards developing inhibitors that target single enzymes is waning, with a noticeable shift towards multi-target inhibitors and combination therapies that address the complexity of diseases.
  3. Basic Mechanistic Studies:
    Although foundational studies on enzyme mechanisms remain important, there is less emphasis on purely mechanistic studies without therapeutic implications, as the journal increasingly prioritizes translational research.

Similar Journals

MOLECULAR DIVERSITY

Advancing Interdisciplinary Research in Chemistry and Biology
Publisher: SPRINGERISSN: 1381-1991Frequency: 4 issues/year

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

ChemMedChem

Pioneering insights for the next generation of pharmaceuticals.
Publisher: WILEY-V C H VERLAG GMBHISSN: 1860-7179Frequency: 24 issues/year

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY

Fostering Collaboration in Life Sciences Research
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1068-1620Frequency: 7 issues/year

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

Current Computer-Aided Drug Design

Innovating Therapeutics: The Future of Drug Design Starts Here
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4099Frequency: 4 issues/year

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

CURRENT MEDICINAL CHEMISTRY

Driving Progress in Chemical and Pharmaceutical Research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8673Frequency: 42 issues/year

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

ARCHIV DER PHARMAZIE

Unveiling Breakthroughs in Drug Discovery and Science
Publisher: WILEY-V C H VERLAG GMBHISSN: 0365-6233Frequency: 12 issues/year

ARCHIV DER PHARMAZIE is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to pioneering advances in the fields of Pharmaceutical Science and Drug Discovery. With an impactful history dating back to its inception in 1822, this journal is recognized for its significant contribution to the pharmaceutical sciences, maintaining an impressive Q2 ranking in both the Drug Discovery and Pharmaceutical Science categories as of 2023. The journal’s commitment to excellence is reflected in its Scopus rankings, placing it in the top tiers of relevant fields, ensuring a broad reach and impact among researchers and professionals. Although Open Access options are not available, ARCHIV DER PHARMAZIE continues to be an invaluable resource for scholars seeking to stay abreast of cutting-edge research and developments in pharmacy and related sciences. The journal’s contributions not only serve as crucial benchmarks in research but also enhance the understanding of pharmaceutical innovations, making it essential reading for both seasoned professionals and students alike.

Future Medicinal Chemistry

Transforming challenges into opportunities in drug development.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

RSC Chemical Biology

Pioneering Research for a Deeper Understanding of Life Processes
Publisher: ROYAL SOC CHEMISTRYISSN: 2633-0679Frequency: 6 issues/year

RSC Chemical Biology is a prestigious journal published by the Royal Society of Chemistry, providing a significant platform for researchers in the fields of biochemistry, genetics, and molecular biology. Launched in 2020, the journal aims to disseminate high-quality research that bridges the gap between chemistry and biology, promoting interdisciplinary studies and innovations that are essential for advancements in life sciences. With an emerging impact factor and ranking in the top quartile (Q1) for multiple categories such as Biochemistry and Molecular Biology, RSC Chemical Biology holds a prominent position in the academic landscape, evidenced by its Scopus rankings placing it in the top 20% and 30% of its respective fields. Although it does not operate under an open-access model, the journal's commitment to accessibility is reflected in its rigorous peer-review process and its role in shaping future scientific discourse. Research published in this journal is vital for contributing to our understanding of complex biological processes and fostering innovations that can lead to real-world applications.

TETRAHEDRON LETTERS

Advancing the Frontiers of Chemical Knowledge
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0040-4039Frequency: 52 issues/year

TETRAHEDRON LETTERS, published by Pergamon-Elsevier Science Ltd, is a leading journal in the fields of Biochemistry, Drug Discovery, and Organic Chemistry, with a rich legacy since its inception in 1959. This prestigious journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of chemical sciences, featuring high-impact research that influences both academic and practical applications. Although it is currently classified in the third quartile across its categories for 2023, its rigorous peer-review process ensures the publication of quality research that contributes to the scientific community. With an ISSN of 0040-4039 and an E-ISSN of 1873-3581, TETRAHEDRON LETTERS is easily accessible for those in the academic landscape seeking to stay abreast of innovative developments. Researchers, professionals, and students alike will find invaluable insights and collaborative opportunities within the pages of TETRAHEDRON LETTERS, making it an essential read for anyone involved in the chemical sciences.

Journal of Molecular Structure

Innovative discoveries shaping the chemistry landscape.
Publisher: ELSEVIERISSN: 0022-2860Frequency: 24 issues/year

Journal of Molecular Structure is a premier publication in the field of chemistry, offering a platform for innovative research that spans analytical, inorganic, organic chemistry, and spectroscopy. Published by Elsevier in the Netherlands, this journal is committed to advancing the understanding of molecular architecture and behavior through high-quality, peer-reviewed articles. With its impressive impact factor and a notable Scopus ranking placing it in the top quartiles among its peers, it serves as an essential resource for researchers, professionals, and students alike. The journal's open access options promote the dissemination of knowledge, ensuring that groundbreaking discoveries reach a broad audience. Established in 1967 and projected to continue through 2025, the Journal of Molecular Structure is vital for anyone engaged in the study of molecular interactions and structural analysis.